<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101331</url>
  </required_header>
  <id_info>
    <org_study_id>AFM13-202</org_study_id>
    <nct_id>NCT04101331</nct_id>
  </id_info>
  <brief_title>Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides</brief_title>
  <acronym>REDIRECT</acronym>
  <official_title>A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affimed GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to evaluate the antitumor activity and safety of AFM13 given as
      monotherapy in patients with CD30-positive T-cell lymphoma. The investigational medicinal
      product AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A)
      recombinant antibody construct which is being developed to treat CD30-positive malignancies.

      Patients who suffer from peripheral T-cell lymphoma or transformed mycosis fungoides, whose
      tumor expresses the surface marker CD30, and who have relapsed after an earlier treatment or
      have refractory disease will be enrolled into this study if all of the study entry criteria
      are fulfilled. Dependent on their disease type and the magnitude of CD30 expression, study
      participants will be assigned to one of 3 study cohorts, each cohort receiving the same
      treatment of weekly AFM13 infusions (a 200mg dose per infusion).

      The main goal of the study is to assess the efficacy of AFM13 treatment as judged by the rate
      of objective responses. Further goals are to assess the safety of AFM13 treatment, the
      immunogenicity of AFM13 (as measured by the potential formation of anti-AFM13 antibodies) and
      the concentration of AFM13 in the blood.

      Approx. 1 month after the last dose of AFM13 there will be a final study visit to assess the
      patients' health status after therapy, followed by quarterly phone contacts to check on their
      overall health status and long-term survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity of AFM13: Independent Review Committee (IRC)-confirmed objective response rate (ORR)</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Assessed by the modified Lugano Classification (Cheson, 2014) for Cohorts A and B (PTCL) and after at least 8 weeks from the first assessment as assessed by Olsen Criteria (Olsen, 2011) for Cohort C (TMF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of AFM13: Investigator-assessed objective response rate (ORR-2)</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Assessed by the modified Lugano Classification (Cheson, 2014) for Cohorts A and B (PTCL) and after at least 8 weeks from the first assessment as assessed by Olsen Criteria (Olsen, 2011) for Cohort C (TMF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response to AFM13 (DOR)</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Assessed by the modified Lugano Classification (Cheson, 2014) for Cohorts A and B (PTCL) and after at least 8 weeks from the first assessment as assessed by Olsen Criteria (Olsen, 2011) for Cohort C (TMF )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of AFM13</measure>
    <time_frame>From screening till final study visit (30-37 days after last dose)</time_frame>
    <description>Number and frequency of Adverse Events, which includes clinical significant abnormal findings in safety laboratory, vital signs and ECG assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AFM13</measure>
    <time_frame>During Cycle 1 (each cycle is 56 days)</time_frame>
    <description>Cmax (maximum measured concentration of the analyte in plasma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of AFM13</measure>
    <time_frame>During Cycle 1 (each cycle is 56 days)</time_frame>
    <description>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of AFM13</measure>
    <time_frame>During Cycle 1 (each cycle is 56 days)</time_frame>
    <description>Vss (Volume of distribution at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of AFM13</measure>
    <time_frame>During Cycle 1 (each cycle is 56 days)</time_frame>
    <description>t1/2 (Terminal half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AFM13</measure>
    <time_frame>From screening till final study visit (30-37 days after last dose)</time_frame>
    <description>Maximum change from baseline of anti-drug antibodies (ADA) in blood and their neutralizing potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Through study completion, up to 12 months</time_frame>
    <description>QoL as measured by the European Quality of Life 5-dimensional questionnaire (EQ-5D) for Cohorts A and B; and by Skindex-29 for Cohort C</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Transformed Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to &lt;10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFM13</intervention_name>
    <description>weekly intravenous infusions of 200mg</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Histologically confirmed CD30-positive PTCL (most subtypes allowed) or TMF per the
             revised World Health Organization 2016 classification (Swerdlow, 2016) by central
             assessment.

          -  Cohorts A and B (PTCL cohorts): measurable by the modified Lugano Classification
             (Cheson, 2014); measurable disease of ≥1.5 cm diameter by computed tomography (CT),
             assessed locally for eligibility. Note: fluorodeoxyglucose (FDG) avid disease by
             positron emission tomography (PET) recommended, if possible.

          -  Cohort C (TMF cohort): measurable by the Olsen Criteria (Olsen, 2011) including at
             least 1 cutaneous lymphoma lesion ≥2 cm in diameter, assessed locally for eligibility.

          -  Patients must have relapsed or refractory disease AND the following:

          -  Cohorts A and B (PTCL): patients must have received at least 1 prior line of systemic
             therapy. For patients with systemic ALCL, patients must have failed or be intolerant
             to brentuximab vedotin [BV]; Adcetris®

          -  Cohort C (TMF): patients must have received at least 1 prior line of systemic therapy;
             and have exhausted systemic therapies with regular approval for their disease

        Main Exclusion Criteria:

          -  Patients with the following subtypes of lymphoma: T-cell prolymphocytic leukemia;
             T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK
             cells; Aggressive NK-cell leukemia; Extranodal NK-/T-cell lymphoma; Indolent T-cell
             lymphoproliferative disorder of the GI tract:

          -  Has had an allogenic tissue hematopoietic cell/solid organ transplant within the last
             3 years. Note: Patients who have had a transplant &gt;3 years ago are eligible as long as
             there are no signs/symptoms of graft versus host disease (GvHD).

          -  Requirement for systemic immunosuppressive therapy, e.g. GvHD therapy, &lt;12 weeks prior
             to the first dose of study drug.

          -  Prior treatment with AFM13
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassandra Choe-Juliak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Affimed Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Seog Kim, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia Schwarz, PhD</last_name>
    <phone>+ 49 6221 6743</phone>
    <phone_ext>620</phone_ext>
    <email>s.schwarz@affimed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Zain, Dr</last_name>
      <phone>626-218-1133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA) Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Eradat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Lymphoid Malignancies</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Shong</last_name>
    </contact>
    <investigator>
      <last_name>Ahmed Sawas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chizobam Obam</last_name>
      <phone>713-794-3074</phone>
      <email>ciobi@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Mok</last_name>
      <phone>713-792-1871</phone>
      <email>idmok@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cody Hammer</last_name>
      <phone>206-606-1286</phone>
      <email>chammer@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Shustov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pratyush Giri, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryone Kuss, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health-Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Shortt, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Gasiorowski, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasman Armytage, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dejan Radeski, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal K Bouabdallah, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Maisonneuve, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia E Oncologia Medica L.E A.Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Musuraca, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Ravano, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale di Ravenna - Ospedale S. Maria delle Croci di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Yong Kwak, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Seok Lee, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-Seong Eom, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Seog Kim, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Cheol Jo, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o.. Szpital Morski im. PCK, Oddzial Hematologii i Transplantologii Szpiku</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Knopinska-Posluszny, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Jurczak, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republic Hospital n.a. V.A. Baranov</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Myasnikov, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First State Saint-Petersburg Pavlov Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Afanasyev, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Shelekhova, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GUZ Leningrad Regional Clinical Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Uspenskaya, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Voloshin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Volodicheva, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duran I Reynals Hospital Catalan Institute Of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Domingo Domenech, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana Novelli, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Sanchez Gonzales, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Marin Niebla, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Sancho Cia, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d' Oncologia Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Maria Roncero Vidal, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre-Centro de Actividades Ambulatorias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Rodriguez, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima de la Cruz Vicente, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Faculty of Medicine, Department of Internal Diseases, Hematology Division</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhit Ozcan, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim Arastirma Hastanesi Hematoloji Klinigi Ankara</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fevzi Altuntas, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gazi University Faculty of Medicine, Department of Internal Diseases</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munci Yagci, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sağlık Bilimleri Üniversitesi Gülhane Eğitim ve Araştırm Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meltem Aylı, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bilim Dali Fatih</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meliha Nalcaci, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fahri Sahin, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Faculty of Medicine, Department of Internal Diseases, Hematology Division</name>
      <address>
        <city>İzmit</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozgur Mehtap, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Egitim Merkezi</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Turgut, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tekirdag Namik Kemal Universitesi Saglik Uygulama ve Arastirma Hastanesi</name>
      <address>
        <city>Tekirdag</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burhan Turgut, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KaradenizTeknik Universitesi Tip Fakultesi Farabi Hastanesi</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Sonmez, Prof Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

